Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.

摘要

Recently, Dulucq and coworkers reported that multidrag resistance gene (MDR1) polymorphisms were associated with major molecular responses (MMRs) to standard-dose imatinib in chronic my-eloid leukemia (CML). Significantly more patients homozygous for allele 1236T achieved a MMR. Patients with this genotype had also higher imatinib concentrations. These findings suggested a better response in patients with the TT genotype.